Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Monovalent mRNA Influenza Vaccine
NCT06118151Phase 1Completed
- Sponsor
- Sanofi
- Start
- Apr 2022
- Primary completion
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of influenza hemagglutinin mRNA vaccine in influenza (6 cohorts), sponsored by Sanofi. Primary endpoints: Presence of any unsolicited systemic adverse events (AEs) reported in the 30 minutes after injection, Presence of solicited injection site reactions at 7 days and 5 more. Started Apr 2022; status: completed.
02
Drugs
influenza hemagglutinin mRNA vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06118151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118151.